Miracor Medical Systems GmbH, a Vienna, Austria medical device company that is commercializing a new technology for improving outcomes for heart attack patients, has secured €7m (approximately $10m) in the first closing of its Series B financing round.
Participants include Austria Wirtschaftsservice (aws), SHS Gesellschaft für Beteiligungsmanagement, as well as the existing investors Earlybird and Delta Partners.
This brings the total amount raised by the company to date to €14.9m ($21.3m) in venture capital and grants.
Miracor intends to use the funds to initiate clinical trials and sales activities in select hospitals in Europe.
Founded in 2008 and led by Jon H. Hoem, Miracor is commercializing its CE-marked impulse system, PICSO®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. It and can be used during coronary revascularization procedures following myocardial infarction and other types of acute coronary syndromes to intermittently increase the pressure in the coronary venous system.